Spectris purchased the company from the private equity firm Equistone Partners.
Michael Fort, executive chairman of Concept Life Sciences, told us that Concept Life Sciences will be a standalone operating company within the Materials Analysis business segment of Spectris, retaining its own brand identity. Fort and the current management team will continue to run the business.
Fort said Concept customers will benefit from the additional expertise that can be delivered from Spectris' other operating companies, including Malvern Panalytical and Particle Measuring Systems, which make up its Materials Analysis business segment.
These companies develop products to help customers improve the accuracy and speed of materials analysis in the laboratory and meet a growing demand for contamination monitoring solutions in quality and process control, he explained.
“Over time, as the business continues to expand its capabilities and geographic presence and sees benefits delivered from the specific areas of expertise from Malvern Panalytical, customers should see more of a focus on solutions,” he said, explaining that Spectris’ intention is to accelerate internationalization and expansion of service lines.
“Additional expertise that can be delivered from other Spectris operating companies includes particle characterization and microbiology expertise at Malvern Panalytical, as well as an expanded global support team,” he added.
“The leadership team at Spectris is passionate about the potential for the business and has a strong interest in developing and investing in Concept Life Sciences’ capabilities, facilities and its highly talented scientific team."